Gio's Law, which would enable law enforcement to carry EpiPens, heads to Congress
The bill carries the name of a Long Island boy.
It has been 12 years since Georgina Cornago lost her son, Giovanni, to a peanut allergy attack. Now, her years of hard work have culminated in a congressional bill with her son's name on it.
"To say I'm emotional is an understatement," Cornago said. "I just lost it. I broke down."
Cornago is a warrior for allergy awareness. She started with her small village, Lynbrook. Every police car there now is equipped with an epinephrine auto injector as a result of her efforts. They've already saved two lives there.
"The police officer is the one to respond to the call. There are just so many ambulances, but there's a much more prevalent number of police," Lynbrook Police Inspector Sean Murphy said.
"There's no reason we are losing lives"
Giovanni Cornago
CBS News New York
Gio's life might have been saved if officers had carried the devices at the time. The ninth grader ate trail mix he didn't know contained peanuts. His heart stopped on the way to the hospital.
CBS News New York first spoke with Cornago more than a decade ago.
"I definitely wasn't prepared, and I don't think anyone is prepared for that to happen," Cornago told CBS News New York in 2013.
Since then, Cornago has been on a mission to make sure others are prepared. Gio's Law, which enables law enforcement to carry the devices, is in effect in New York state, including Suffolk County. Nassau County has been a holdout, amid debate over costs and liability.
The bipartisan congressional bill would establish a grant program to equip law enforcement across the country with EpiPens and similar devices, and to provide training to officers.
CBS News New York
"From bee stings, from nut allergies, from mold allergies, and there is no reason we are losing lives simply because we don't have the equipment we need," Rep. Laura Gillien said.
Cornago said she believes concerns over liability can be overcome.
"What's the worst that can happen? Somebody can die because you didn't give the EpiPen. That is the worst that can happen," Cornago said.
Cornago said if police cars are equipped with Narcan, they should also carry epinephrine. Seconds count when anaphylaxis occurs.
As she heads to the national stage to continue her mission, Cornago said she is reminded of a promise she made to Gio.
"His death would not be in vain, and his life would have purpose, and I think I am doing that," she said.
The bill is also sponsored by Republican Rep. Andrew Garbarino.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
July in Review: 13 Top Health Press Releases
A roundup of the most newsworthy healthcare press releases from PR Newswire, including FDA approval for Aktiia's cuffless blood pressure monitor, Cochlear's new smart cochlear implant system and Varda's $187M Series C funding for space medicine. NEW YORK, Aug. 8, 2025 /PRNewswire/ -- With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the month's most popular releases and newsworthy trends, here's a recap of some of the past month's most read- and engaged-with stories. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Lorient Closes $500 Million Fund III to Scale Founder-Led Healthcare CompaniesLorient partners with founder-led healthcare companies in the middle market, bringing sector expertise, hands-on operational capabilities, and a repeatable approach to scaling mission-driven businesses. The firm has built a track record of supporting improvements in clinical outcomes, workforce efficiency, and access to care across the U.S. healthcare system. Medicare Drug Pricing Changes Threaten Patient Access to Life-Saving Treatments The brief highlights concerns that the next round of negotiations under the Inflation Reduction Act may unintentionally restrict access to vital medications for Medicare patients. The Centers for Medicare & Medicaid Services' upcoming drug price negotiation program, which includes medications covered by Medicare Part B, would take effect in 2028. OpenEvidence, the Fastest-Growing Application for Physicians in History, Announces $210 Million Round at $3.5 Billion ValuationOpenEvidence rapidly surfaces relevant medical knowledge, synthesizes medical research, and gives clinicians the power to make faster, more evidence-based decisions—accelerating both medical literature review and clinical decision support. By reducing the lag between new evidence and bedside application, OpenEvidence enables improved patient outcomes. Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations "We are proud to have developed ZEGFROVY, a first-in-class oral therapy that offers a more effective treatment option with enhanced safety and ease of administration for NSCLC patients with EGFR exon20ins," said Dr. Xiaolin Zhang, CEO of Dizal. Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch Ategenos has been quietly developing a novel platform that integrates pharmaceutical science with real-time digital health technologies to address adherence in critical dose management. The company will share details on its SmartPatch platform and initial partnerships in the coming weeks. The Villages Health ("TVH") Announces Strategic Restructuring and Agreement to be Acquired by CenterWell "Under CenterWell, this healthcare system will continue to be a leading provider of patient-centered, primary care-driven and community-based healthcare. Our primary goal remains to keep our patients healthy and to heal them quickly, as it has always been from the inception of TVH," said Dr. Elliot Sussman, Chairman of the Board and physician founder of The Villages Health. Cochlear Launches World's First and Only Smart Cochlear Implant System This new firmware update pathway will enhance recipients' sound processor upgrades to deliver their best possible hearing experience, giving recipients more ways to access new innovations over time. It is also the first implant with internal memory, which enables unique hearing settings (MAPs) to be securely stored in the implant itself which can be easily transferred to any Nucleus Nexa Sound Processor in the future. Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions Monogram's semi- and fully autonomous robotic technologies are expected to add new and differentiated capabilities to expand Zimmer Biomet's flagship ROSA® Robotics platform and broad suite of navigation and enabling technologies. Monogram has developed a CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology, which received FDA 510(k) clearance in March 2025 and is expected to be commercialized with Zimmer Biomet implants in early 2027. Aktiia's Hilo Band Becomes First Cuffless Blood Pressure Monitor Cleared by FDA for Over-the-Counter Use The milestone sets a new global benchmark for how blood pressure can be effortlessly monitored through wearable, user-friendly technology. With this FDA clearance, Aktiia is now positioned to establish Hilo as the category-defining wearable for cuffless blood pressure monitoring in the U.S. and beyond. Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology The benefits from GSK's therapy area expertise, deep understanding of disease biology, clinical development capability and global commercial scale with Hengrui Pharma's early discovery engine, platform technologies, extensive pre-clinical pipeline of high-value programs and speed of clinical evaluation. Varda Announces $187 million in Series C Funding to Make Medicines in Space Varda's orbital laboratories are the first to process materials outside the International Space Station and mark the beginnings of commercial expansion into low Earth orbit. Due to the lack of gravity, materials such as the active pharmaceutical ingredients in medicines crystallize differently than they would on Earth, creating novel drug formulations that would otherwise be impossible. Waystar to Acquire Iodine Software, Accelerating the AI-Powered Transformation of Healthcare Payments The proposed transaction is expected to accelerate Waystar's ability to transform healthcare payments through its leading cloud-based software platform, empowering more than one million providers with advanced AI capabilities to prevent denials, reduce manual work, and improve financial performance. Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing The combined company will continue to operate under the Waters name and retain its listing on the New York Stock Exchange under the ticker symbol WAT. Waters' headquarters will remain in Milford, Mass., and the combined company will maintain a significant presence where the BD Biosciences & Diagnostic Solutions business currently operates. For more news like this, check out all of the latest health-related releases from PR Newswire. Trending Topics Among the health news that was distributed in July, the PR Newswire team was able spot several larger stories that highlight the trends shaping the industry. OBBA: The passage of the One Big Beautiful Bill Act (OBBBA) saw health providers and advocacy groups responding with both concern and praise. Shatterproof, a non-profit dedicated to reducing the burden of substance use disorder in the U.S., found itself on both sides of the bill in its statement applauding the inclusion of the permanent closure of the de minimis loophole, while also being "deeply concerned about the bill's potential impact on access to treatment for individuals living with substance use disorder (SUD)." ENDO 2025: The Endocrine Society's annual meeting took place in San Francisco July 12-15 and drew over 7,000 attendees, nearly 2,500 abstracts and over 200 other sessions. Tyra Biosciences announced details of its abstract to be presented at the meeting. Neurocrine Biosciences sent several ENDO-related announcements, including its presentation of one-year data showing the efficacy of CRENESSITY® (crinecerfont) in adults. To support this, Neurocrine presented data from the CAHtalog® Registry that showed patients are still exposed to excess glucocorticoids and often do not meet clinical targets, which underscores an unmet need that could be filled by CRENESSITY®. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at For more news like this, check out all of the latest health-related releases from PR Newswire. View original content to download multimedia: SOURCE PR Newswire
Yahoo
34 minutes ago
- Yahoo
Experts reveal the hidden health side effects of lash serums
Longer, darker lashes are having a moment. For those avoiding the risk or expense of lash extensions, serums can seem like a safer, more affordable option. But not all lash serums are created equal – and some come with hidden side-effects. The key difference lies in the ingredients. Some lash serums use conditioning agents like peptides or plant oils, while others contain powerful pharmaceutical ingredients originally developed for treating eye disease. In 2001, a new medication called bimatoprost was approved to treat glaucoma and ocular hypertension – two conditions involving pressure buildup inside the eye that can damage the optic nerve and cause vision loss. Unlike earlier treatments, bimatoprost worked well for patients who hadn't responded to other drugs, had fewer systemic side effects (effects on the whole body rather than just the eye) and required less frequent dosing than some other glaucoma drops. But doctors soon noticed something unexpected: their patients' eyelashes were growing longer, thicker and darker. Researchers still don't fully understand how bimatoprost stimulates lash growth, but it appears to extend the anagen phase – the active growth phase – of the lash life cycle. In 2008, the same drug (now marketed as Latisse) was approved by the US Food and Drug Administration (FDA), the federal agency responsible for evaluating the safety and effectiveness of drugs and medical devices, to treat eyelash hypotrichosis, a condition where eyelashes are sparse or missing. It was initially prescribed for people who had lost their lashes due to chemotherapy, alopecia areata (an autoimmune disorder causing hair loss), or trichotillomania (a compulsive hair-pulling condition). Extensive research shows that bimatoprost is effective at making lashes longer, thicker and darker, with noticeable results after 16 weeks of daily use. But the results are temporary: once you stop using it, your lashes return to their natural growth cycle. Side-effects Bimatoprost belongs to a class of medications called prostaglandin analogues (PGAs), which have been widely used in eye care since the 1990s. Because of this, its side effects are well documented. When used for lash growth, bimatoprost can cause burning, redness, dryness and eye irritation. These usually go away when the product is stopped. But there are also more serious cosmetic changes to be aware of, including darkening of the skin on the eyelid, fat loss around the eyes, creating a hollow, sunken look, permanent iris darkening (the coloured part of the eye), unwanted hair growth where the serum spreads and, in rare cases, drooping of the upper eyelid, which may require surgery to correct. In the UK, bimatoprost remains a prescription-only medication. However, the boom in over-the-counter lash serums sold online and in shops has made similar products more accessible – and potentially more confusing. A recent investigation by the UK government found that almost one in four lash serums sold in the UK contain PGAs such as isopropyl cloprostenate. This chemical is not as well studied as bimatoprost, but case reports suggest it can cause skin darkening, dryness and hollowing of the eye area, sometimes after just a few weeks of use. In the US, the FDA issued warnings over a decade ago stating that any cosmetic product containing these ingredients and making growth claims should be treated as a drug, not a cosmetic. Consumers may be unaware they're using a pharmaceutical-mimicking ingredient. Sweden banned PGAs in lash serums in 2013. Canada prohibits them in all cosmetic products. Even if a product claims to be 'PGA-free,' check the ingredients list: anything ending in '-prost' is a red flag. 'Natural' or peptide-based alternatives Some lash serums use peptides, which may help strengthen lashes by boosting keratin or supporting follicle health. These are often combined with conditioning agents to reduce breakage. While seen as a gentler alternative to PGAs, most studies on peptides focus on scalp hair, not eyelashes, so evidence for lash growth is limited. Other serums rely on castor oil or plant-based extracts, but their effectiveness is largely anecdotal and not supported by robust science. There is no guaranteed, side-effect-free way to make lashes grow dramatically longer. Prescription lash serums like bimatoprost are proven to work – but they come with potential risks, especially with long-term use. Over-the-counter products may seem safer, but many contain hidden prostaglandin analogues buried deep in the ingredients list with similar side effects. Peptide and oil-based serums are less risky, but there's little strong evidence that they work. Our eyes are delicate and, unlike beauty trends, they're not replaceable. If you're thinking about enhancing your lashes, read the label, do your research and speak to an eye care professional. The price of longer lashes shouldn't be your eye health. Alison Ng is a Lecturer in Optometry and Vision Sciences at Cardiff University Byki Huntjens is an Honorary Senior Research Fellow in Optometry in the School of Health & Medical Sciences, City St George's at the University of London. This article is republished from The Conversation under a Creative Commons license. Read the original article.
Yahoo
34 minutes ago
- Yahoo
Lee Health gains NMTC financing for new medical facility in US
Lee Health, a not-for-profit health system in the US, has secured a $6m New Markets Tax Credit (NMTC) allocation from UB Community Development (UBCD) on permanent financing for a new medical facility. The financing will facilitate the purchase, along with the installation of equipment in the facility in Fort Myers, Florida, aimed at bolstering healthcare services in a low-income community. The to-be-constructed facility will offer an 85,000ft² medical laboratory and data centre, which will enhance Lee Health's processing and testing capabilities. This expansion is expected to support the health system's existing operations and provide essential medical lab services to more than 100,000 people each year. Lee Health chief operating and financial officer Ben Spence said: "This investment allows Lee Health to expand critical infrastructure that supports the delivery of high-quality, efficient care across our region. "We are grateful for the opportunity to better serve our community, while also creating meaningful jobs and strengthening our ability to meet the growing needs of Southwest Florida." The project is set to create 30 new jobs while retaining 142 existing positions across the facilities of Lee Health. With a network that includes four acute care hospitals, two nursing units, a paediatric hospital, and multiple outpatient centres, the health system provides services for over two million patients annually. It is particularly focused on reaching medically underserved individuals, offering access to social services and primary care that might otherwise be sought in emergency rooms. UB Community Development president Alex Jones said: "With healthcare being so vital to a community and the uncertain future facing providers, UBCD is grateful to be able to support Lee Health in their undertaking.' Earlier this year, North Walton Doctors Hospital received $12.5m in NMTC funding through UBCD for its rehabilitation. "Lee Health gains NMTC financing for new medical facility in US" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
